InMed Pharmaceuticals Inc.
INM
$2.12
-$0.23-9.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.30M | 1.26M | 1.11M | 1.26M | 1.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.30M | 1.26M | 1.11M | 1.26M | 1.28M |
| Cost of Revenue | 728.10K | 1.09M | 650.80K | 771.20K | 817.00K |
| Gross Profit | 576.70K | 175.60K | 460.90K | 493.40K | 466.10K |
| SG&A Expenses | 2.25M | 1.33M | 1.55M | 1.42M | 1.76M |
| Depreciation & Amortization | 52.80K | 52.30K | 53.20K | 54.60K | 54.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.15M | 3.38M | 3.32M | 3.02M | 3.29M |
| Operating Income | -1.84M | -2.12M | -2.21M | -1.75M | -2.01M |
| Income Before Tax | -1.79M | -2.12M | -2.58M | -1.68M | -1.93M |
| Income Tax Expenses | -- | -- | -- | -- | 7.10K |
| Earnings from Continuing Operations | -1.79M | -2.12M | -2.58M | -1.68M | -1.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.79M | -2.12M | -2.58M | -1.68M | -1.94M |
| EBIT | -1.84M | -2.12M | -2.21M | -1.75M | -2.01M |
| EBITDA | -1.79M | -2.06M | -2.15M | -1.70M | -1.95M |
| EPS Basic | -1.20 | -1.94 | -3.64 | -2.71 | -4.04 |
| Normalized Basic EPS | -0.75 | -1.21 | -2.28 | -1.69 | -2.51 |
| EPS Diluted | -1.20 | -1.94 | -3.64 | -2.71 | -4.04 |
| Normalized Diluted EPS | -0.75 | -1.21 | -2.28 | -1.69 | -2.51 |
| Average Basic Shares Outstanding | 1.49M | 1.10M | 706.50K | 620.10K | 479.90K |
| Average Diluted Shares Outstanding | 1.49M | 1.10M | 706.50K | 620.10K | 479.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |